FindTrial
Sign In

Descartes-08

DRUG6 trials

Sponsors

Cartesian Therapeutics Inc., Cartesian Therapeutics

Conditions

ANCA-Associated Vasculitis (AAV)Antisynthetase SyndromeChildhood-onset Systemic Lupus ErythematousJuvenile DermatomyositisJuvenile Myasthenia GravisMultiple MyelomaMyasthenia Gravis, GeneralizedSystemic Lupus Erythematosus (SLE)

Phase 1

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
TerminatedNCT03448978
Cartesian TherapeuticsMultiple Myeloma
Start: 2018-03-08End: 2021-06-03Updated: 2024-07-01
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
RecruitingNCT07089121
Cartesian TherapeuticsANCA-Associated Vasculitis (AAV), Childhood-onset Systemic Lupus Erythematous, Juvenile Dermatomyositis +1
Start: 2026-01-14End: 2028-12-01Target: 50Updated: 2026-07-27

Phase 2

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Active, not recruitingNCT04146051
Cartesian TherapeuticsMyasthenia Gravis, Generalized
Start: 2019-12-04End: 2026-09-30Target: 30Updated: 2026-08-14
Descartes-08 for Patients With Systemic Lupus Erythematosus
Active, not recruitingNCT06038474
Cartesian TherapeuticsSystemic Lupus Erythematosus (SLE)
Start: 2024-02-12End: 2027-12-01Updated: 2026-03-27
Descartes-08 in Autoantibody Myositis
RecruitingNCT07391605
Cartesian TherapeuticsAntisynthetase Syndrome
Start: 2026-04-28End: 2028-05-01Target: 60Updated: 2026-08-17

Phase 3

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)
RecruitingCTIS2024-520355-25-00
Cartesian Therapeutics Inc.generalized myasthenia gravis
Start: 2025-10-10Target: 29Updated: 2025-09-30

Related Papers

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.
2026-01-09
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
2026-01-09
Durability of Response to B‐Cell Maturation Antigen‐Directed <scp>mRNA</scp> Cell Therapy in Myasthenia Gravis
Annals of Clinical and Translational Neurology2025-08-264 citations
Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease
Blood2024-11-054 citations
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
2023-07-01151 citations
Unleashing the full potential of cell therapy through RNA engineering
Cell and Gene Therapy Insights2022-05-19
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
2020-07-0672 citations
Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma
Blood2019-11-132 citations